These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 22644023)

  • 21. Isolation and characterization of a new Clostridium difficile ribotype during a prospective study in a hospital in Italy.
    Sisto F; Maraschini A; Fabio G; Serafino S; Zago M; Scaltrito MM; Castaldi S
    Curr Microbiol; 2015 Feb; 70(2):151-3. PubMed ID: 25240292
    [No Abstract]   [Full Text] [Related]  

  • 22. Comparison of resistance against erythromycin and moxifloxacin, presence of binary toxin gene and PCR ribotypes in Clostridium difficile isolates from 1990 and 2008.
    Ilchmann C; Zaiss NH; Speicher A; Christner M; Ackermann G; Rohde H
    Eur J Clin Microbiol Infect Dis; 2010 Dec; 29(12):1571-3. PubMed ID: 20632051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of Highly Specific Diversity-Oriented Synthesis-Derived Inhibitors of Clostridium difficile.
    Duvall JR; Bedard L; Naylor-Olsen AM; Manson AL; Bittker JA; Sun W; Fitzgerald ME; He Z; Lee MD; Marie JC; Muncipinto G; Rush D; Xu D; Xu H; Zhang M; Earl AM; Palmer MA; Foley MA; Vacca JP; Scherer CA
    ACS Infect Dis; 2017 May; 3(5):349-359. PubMed ID: 28215073
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tetracycline resistance gene tet(W) in the pathogenic bacterium Clostridium difficile.
    Spigaglia P; Barbanti F; Mastrantonio P
    Antimicrob Agents Chemother; 2008 Feb; 52(2):770-3. PubMed ID: 18070963
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.
    Peláez T; Alcalá L; Alonso R; Rodríguez-Créixems M; García-Lechuz JM; Bouza E
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1647-50. PubMed ID: 12019070
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clostridium difficile isolates resistant to fluoroquinolones in Italy: emergence of PCR ribotype 018.
    Spigaglia P; Barbanti F; Dionisi AM; Mastrantonio P
    J Clin Microbiol; 2010 Aug; 48(8):2892-6. PubMed ID: 20554809
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of LFF571 and vancomycin in patients with moderate Clostridium difficile infections.
    Bhansali SG; Mullane K; Ting LS; Leeds JA; Dabovic K; Praestgaard J; Pertel P
    Antimicrob Agents Chemother; 2015 Mar; 59(3):1441-5. PubMed ID: 25534724
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clostridium difficile bacteremia, Taiwan.
    Lee NY; Huang YT; Hsueh PR; Ko WC
    Emerg Infect Dis; 2010 Aug; 16(8):1204-10. PubMed ID: 20678312
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The (p)ppGpp Synthetase RSH Mediates Stationary-Phase Onset and Antibiotic Stress Survival in Clostridioides difficile.
    Pokhrel A; Poudel A; Castro KB; Celestine MJ; Oludiran A; Rinehold AJ; Resek AM; Mhanna MA; Purcell EB
    J Bacteriol; 2020 Sep; 202(19):. PubMed ID: 32661079
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Possible seasonality of Clostridium difficile in retail meat, Canada.
    Rodriguez-Palacios A; Reid-Smith RJ; Staempfli HR; Daignault D; Janecko N; Avery BP; Martin H; Thomspon AD; McDonald LC; Limbago B; Weese JS
    Emerg Infect Dis; 2009 May; 15(5):802-5. PubMed ID: 19402975
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasmid Acquisition Alters Vancomycin Susceptibility in Clostridioides difficile.
    Pu M; Cho JM; Cunningham SA; Behera GK; Becker S; Amjad T; Greenwood-Quaintance KE; Mendes-Soares H; Jones-Hall Y; Jeraldo PR; Chen J; Dunny G; Patel R; Kashyap PC
    Gastroenterology; 2021 Feb; 160(3):941-945.e8. PubMed ID: 33197449
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The tcdA-negative and tcdB-positive Clostridium difficile ST81 clone exhibits a high level of resistance to fluoroquinolones: a multi-centre study in Beijing, China.
    Cheng JW; Liu C; Kudinha T; Xiao M; Fan X; Yang CX; Wei M; Liang GW; Shao DH; Xiong ZJ; Hou X; Yu SY; Wang Y; Yang QW; Su JR; Xu YC
    Int J Antimicrob Agents; 2020 Jul; 56(1):105981. PubMed ID: 32330584
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital.
    Curry SR; Marsh JW; Shutt KA; Muto CA; O'Leary MM; Saul MI; Pasculle AW; Harrison LH
    Clin Infect Dis; 2009 Feb; 48(4):425-9. PubMed ID: 19140738
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Future novel therapeutic agents for Clostridium difficile infection.
    Koo HL; Garey KW; Dupont HL
    Expert Opin Investig Drugs; 2010 Jul; 19(7):825-36. PubMed ID: 20521993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections.
    Mullane K; Lee C; Bressler A; Buitrago M; Weiss K; Dabovic K; Praestgaard J; Leeds JA; Blais J; Pertel P
    Antimicrob Agents Chemother; 2015 Mar; 59(3):1435-40. PubMed ID: 25534727
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metronidazole resistance in Clostridium difficile is heterogeneous.
    Peláez T; Cercenado E; Alcalá L; Marín M; Martín-López A; Martínez-Alarcón J; Catalán P; Sánchez-Somolinos M; Bouza E
    J Clin Microbiol; 2008 Sep; 46(9):3028-32. PubMed ID: 18650353
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antimicrobial resistance in Clostridioides (Clostridium) difficile derived from humans: a systematic review and meta-analysis.
    Sholeh M; Krutova M; Forouzesh M; Mironov S; Sadeghifard N; Molaeipour L; Maleki A; Kouhsari E
    Antimicrob Resist Infect Control; 2020 Sep; 9(1):158. PubMed ID: 32977835
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ErmB determinants and Tn916-Like elements in clinical isolates of Clostridium difficile.
    Spigaglia P; Carucci V; Barbanti F; Mastrantonio P
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2550-3. PubMed ID: 15917571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Clostridium difficile cpr locus is regulated by a noncontiguous two-component system in response to type A and B lantibiotics.
    Suárez JM; Edwards AN; McBride SM
    J Bacteriol; 2013 Jun; 195(11):2621-31. PubMed ID: 23543720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clostridium difficile infection: new developments in epidemiology and pathogenesis.
    Rupnik M; Wilcox MH; Gerding DN
    Nat Rev Microbiol; 2009 Jul; 7(7):526-36. PubMed ID: 19528959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.